SEC Company Response from VYNE Therapeutics Inc. (VYNE) (CIK 0001566044) (VYNE) — Jan 6, 2020
VYNE Therapeutics Inc. (VYNE) (CIK 0001566044)
Date: Jan. 6, 2020 · CIK: 0001566044 · Accession: 0001193125-20-002247
AI Filing Summary & Sentiment
File numbers found in text: 333-235351
Letter
Menlo Therapeutics, Inc.
200 Cardinal Way, 2nd Floor
Redwood City, California 94063
January 6,
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-6010
Re: Menlo Therapeutics, Inc. Registration Statement on Form S-4 (File No. 333-235351)
Request for Acceleration of Effectiveness
Requested Date: January 7, 2020
Requested Time: 4:30 p.m. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 promulgated under the Securities Act of 1933, as amended, Menlo Therapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effective date of the Registration Statement on Form S-4 (File No. 333-235351), as amended (the “Registration Statement”), so that it may become effective at 4:30 p.m. Eastern Time on January 7, 2020, or as soon as possible thereafter. The Registrant hereby authorizes Mark V. Roeder, of Latham & Watkins LLP, to orally modify or withdraw this request for acceleration.
Thank you for your assistance. We request that we be notified of such effectiveness by a telephone call to Mr. Roeder at (650) 463-3043, or in his absence Miles P. Jennings, of Latham & Watkins LLP, at (650) 463-3063. We also respectfully request that a copy of the written order from the Commission verifying the effective time and date of such Registration Statement be sent to Latham & Watkins LLP, attention: Mark V. Roeder, via facsimile at (650) 463-2600.
Very truly yours,
Menlo Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Menlo Therapeutics, Inc. 200 Cardinal Way, 2nd Floor Redwood City, California 94063 January 6, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Re: Menlo Therapeutics, Inc. Registration Statement on Form S-4 (File No. 333-235351) Request for Acceleration of Effectiveness Requested Date: January 7, 2020 Requested Time: 4:30 p.m. Eastern Time Ladies and Gentlemen: In accordance with Rule 461 promulgated under the Securities Act of 1933, as amended, Menlo Therapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effective date of the Registration Statement on Form S-4 (File No. 333-235351), as amended (the “Registration Statement”), so that it may become effective at 4:30 p.m. Eastern Time on January 7, 2020, or as soon as possible thereafter. The Registrant hereby authorizes Mark V. Roeder, of Latham & Watkins LLP, to orally modify or withdraw this request for acceleration. Thank you for your assistance. We request that we be notified of such effectiveness by a telephone call to Mr. Roeder at (650) 463-3043, or in his absence Miles P. Jennings, of Latham & Watkins LLP, at (650) 463-3063. We also respectfully request that a copy of the written order from the Commission verifying the effective time and date of such Registration Statement be sent to Latham & Watkins LLP, attention: Mark V. Roeder, via facsimile at (650) 463-2600. Very truly yours, Menlo Therapeutics, Inc. /s/ Steven L. Basta Steven L. Basta President and Chief Executive Officer cc: Mark Roeder, Latham & Watkins LLP Miles Jennings, Latham & Watkins LLP Steven Basta, Menlo Therapeutics, Inc. Kristine Ball, Menlo Therapeutics, Inc. Ronald Krasnow, Menlo Therapeutics, Inc. Mutya Fonte Harsch, Foamix Pharmaceuticals, Ltd. Marie Gibson, Skadden Arps Slate Meagher & Flom LLP